National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Eliglustat (Cerdelga®)

Eliglustat (Cerdelga®) is indicated for the long-term treatment of adult patients with Gaucher disease type 1.


NCPE Assessment Process Completed
Rapid review received  21/03/2016
Rapid review completed  17/05/2016
Rapid Review outcome A Full pharmacoeconomic assessment is recommended
Full pharmacoeconomic assessment commissioned by HSE  31/05/2016
Pre-submission consultation with Applicant  27/09/2016
Submission received from Applicant  09/05/2017
Preliminary review sent to Applicant 07/09/2017
NCPE assessment re-commenced 20/10/2017
Applicant factual accuracy check 27/02/2018
NCPE assessment re-commenced 09/03/2018
NCPE assessment completed 25/04/2018
Full pharmacoeconomic assessment outcome The NCPE recommends that eliglustat (Cerdelga®) should not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. This recommendation should be considered while also having regard to the criteria as specified in the Health (Pricing and Supply of Medical Goods) Act 2013.



The HSE has approved reimbursement following confidential price negotiations September 2018